if you're investing/accelerating the frontier biotech wave here are 4 patterns to watch (bookmark this) 1. the moat is moving from the model to the lab → anthropic runs a wet lab, openai bought orchestra bio, warp sciences raised $215M for ai-run chemistry, and danaher's antibody lab is expected at scale in early 2027 → biohub and partners put $1.8B behind generating the cell data models are missing watch: who owns the proprietary experimental data, not who has the best model 2. deal structure beats geography → the us treasury proposed barring equity, JVs and certain LP stakes in chinese biotech → cash licensing stays outside it. pfizer's $100M stake in 3sbio is the kind of deal it would block, a pure license like bms-hengrui looks unaffected watch: where your co-investors and LPs sit, and whether your China exposure is equity or a license 3. gene editing graduated from promise to phase 3 → one infusion cut hereditary angioedema attacks 87% → a one-time edit dropped LDL up to 62% (phase 1) → a personalized mrna vaccine beat keytruda alone in melanoma watch: delivery and manufacturing speed. design is getting cheap (a guy with chatgpt and alphafold designed his dog's cancer vaccine). making it fast is the bottleneck 4. the FDA is leaning in → dostarlimab got accelerated approval for dMMR rectal cancer, a multi-cancer blood test won a panel vote, and aging is headed into the next regulatory science priorities watch: the endpoint. nobody has defined what "slowing aging" means in a trial yet if you're backing this wave, my DMs are open bio/acc